Spots Global Cancer Trial Database for lintuzumab
Every month we try and update this database with for lintuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002800 | Leukemia Myelodysplastic... Neutropenia | filgrastim lintuzumab cytarabine etoposide idarubicin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) | NCT00502112 | Myelodysplastic... | lintuzumab lenalidomide | 18 Years - | Seagen Inc. | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | NCT00006045 | Leukemia | lintuzumab cytarabine etoposide mitoxantrone hy... | 18 Years - | National Cancer Institute (NCI) | |
| Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | NCT03705858 | Acute Myeloid L... | Ac-Lintuzumab | 18 Years - 99 Years | Columbia University | |
| Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | NCT00002609 | Leukemia | lintuzumab cytarabine idarubicin | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
